Immuron (NASDAQ:IMRN) Stock Short Interest Report for September

Immuron (NASDAQ:IMRN) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 61,753 shares, a drop of 46.6% from the September 15th total of 115,685 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 109,695 shares, the days-to-cover ratio is currently 0.6 days.

Immuron Stock Down 1.3%

Shares of NASDAQ IMRN traded down $0.01 during midday trading on Wednesday, reaching $1.03. The stock had a trading volume of 5,788 shares, compared to its average volume of 762,899. The company’s 50 day moving average price is $1.21 and its 200 day moving average price is $1.09. Immuron has a twelve month low of $0.68 and a twelve month high of $2.39.

Immuron (NASDAQ:IMRN) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The firm had revenue of $1.27 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Immuron Company Profile

Immuron Limited (NASDAQ:IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. Its products are based primarily on antibodies derived from hyperimmune bovine colostrum and are designed to act locally in the gastrointestinal tract rather than enter the bloodstream.

The company’s leading product is Travelan, an oral treatment intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).